Cross Country Healthcare, Inc. (CCRN)
NASDAQ: CCRN · Real-Time Price · USD
14.87
-0.02 (-0.13%)
At close: Apr 1, 2025, 4:00 PM
14.39
-0.48 (-3.20%)
After-hours: Apr 1, 2025, 4:30 PM EDT
Cross Country Healthcare Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cross Country Healthcare stock have an average target of 18.41, with a low estimate of 18 and a high estimate of 18.61. The average target predicts an increase of 23.81% from the current stock price of 14.87.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cross Country Healthcare stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 4 | 3 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barrington Research | Barrington Research | Hold Maintains $19 | Hold | Maintains | $19 | +25.15% | Mar 14, 2025 |
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 6, 2025 |
| Barrington Research | Barrington Research | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 10, 2024 |
| Truist Securities | Truist Securities | Hold Maintains $15 → $19 | Hold | Maintains | $15 → $19 | +25.15% | Dec 5, 2024 |
| Benchmark | Benchmark | Strong Buy Maintains $19 → $18 | Strong Buy | Maintains | $19 → $18 | +21.05% | Nov 7, 2024 |
Financial Forecast
Revenue This Year
1.28B
from 1.34B
Decreased by -4.91%
Revenue Next Year
1.32B
from 1.28B
Increased by 3.21%
EPS This Year
0.41
from -0.44
EPS Next Year
0.60
from 0.41
Increased by 46.97%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.4B | 1.4B | 1.4B |
| Avg | 1.3B | 1.3B | 1.4B |
| Low | 1.2B | 1.2B | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.1% | 7.4% | 8.3% |
| Avg | -4.9% | 3.2% | 5.2% |
| Low | -12.4% | -2.3% | 1.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.55 | 0.72 | 0.64 |
| Avg | 0.41 | 0.60 | 0.62 |
| Low | 0.22 | 0.37 | 0.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 76.9% | 6.4% |
| Avg | - | 47.0% | 3.4% |
| Low | - | -9.1% | -0.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.